TrialClinical pharmacokinetics2026

A First-in-Human Study of Ulacamten, a Novel Cardiac Myosin Inhibitor for HFpEF.

Justin D Lutz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.